Modality
mRNA
MOA
PD-1i
Target
MET
Pathway
mTOR
Melanoma
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
Dec 2017
→ Jul 2030
Phase 1Current
NCT06117873
1,418 pts·Melanoma
2017-12→TBD·Recruiting
NCT08410713
912 pts·Melanoma
2023-08→2030-07·Completed
2,330 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-211w agoAdCom· Melanoma
2030-07-254.3y awayPh2 Data· Melanoma
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Recruit…
P1/2
Complet…
Catalysts
AdCom
2026-03-21 · 1w ago
Melanoma
Ph2 Data
2030-07-25 · 4.3y away
Melanoma
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06117873 | Phase 1/2 | Melanoma | Recruiting | 1418 | DOR |
| NCT08410713 | Phase 1/2 | Melanoma | Completed | 912 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| Talazasiran | Kymera | NDA/BLA | MET | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| RAP-2478 | Rapport Ther | Phase 3 | MET | |
| Mavuzasiran | Protagonist | Phase 3 | MET |